5FU5 Fluorouracil (chemotherapeutic agent)
References in periodicals archive ?
The other case was not evaluated for the number of tumor cells, owing to the limited size of the biopsy and because the patient was treated with a combination of cetuximab, irinotecan, and 5FU as a first-line therapy.
A recent phase III trial (ACT II), which prescribed radiation with no planned treatment gap and compared cisplatin with 5FU, as well as the role of maintenance chemotherapy, reported a 4 - 5% colostomy rate and over 80% overall survival at 3 years.
More recently the addition of the newer agents oxaliplatin or irinotecan to 5FU has increased response rates to 60% and median survival to 15 months.
Daily oral administration of 2ME2 with 5FU resulted in 84% growth inhibition of established tumors, while treatment with either agent alone was only minimally effective in arresting tumor growth.
Intraperitoneal hyperthermic chemotherapy with mitomycin C and 5FU, at 10[degrees]F above body temperature, has also shown promise.
Because DOX and 5FU have different mechanisms of action, the researchers hypothesized that cells treated with one compound would express a different transcription profile compared with cells treated with the other.
Concurrent radio-sensitizing doses of 5FU were begun along with the radiation therapy.
The researchers noted that the mice treated with a combination of gene therapy plus 5FU "showed a dramatic tumor reduction without adverse effects.
Now he's giving it in conjunction with a new medicine - FUMA - that makes 5FU circulate longer in the bloodstream, thus giving it more of a chance to work.
CDHP increases the activity of 5FU by inhibiting dihydropyrimidine dehydrogenase, the rate-limiting enzyme for the catabolism of 5-FU, while potassium oxonate decreases the gastrointestinal toxicity of 5-FU by preventing phosphorylation in the gastrointestinal tract.
To exert its cytotoxicity, 5FU must first be metabolized to the nucleotide level.